Zenas BioPharma

ZBIO on Nasdaq. Zenas BioPharma develops immunology-based medicines for people with autoimmune diseases. Market value $1.9bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.

Should I look at this?

Not a fit for our list right now

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to September 2026
-15.0%low

For every $100 of what the whole company costs, it produced $-15.01 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to September 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: not known. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$23.85 a share, 77% above its 1-year low

Over the past year the price has ranged from $13.50 to $44.60.

Pays no dividend

Prices from Friday’s close (20 November).

Five years of cash, in billions

-0.1
-0.2
-0.2
2024202512 monthsto Sep '26
Revenue
$5m$10m
Operating margin
-3277.8%-3830.6%
Debt to equity
n/a0.32
Shares outstanding
0.05bn0.07bn

Health checks

  • Free cash flow positive0 of 2 years
  • Accounting checksSkipped: company is not yet profitable
  • Debt0.32× equity
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesNo, 26% more shares since 2024

The quarter to September 2026

How the business did, compared with the same quarter a year earlier.

  • A loss of $109 million, compared with a loss of $51 million a year ago.
  • It loses 4785 cents on each $1 of sales, compared with 1338 cents a year earlier.
  • Over the past 12 months it spent $243 million more cash than it brought in, compared with $159 million a year earlier.
  • 57% more shares than a year ago. Each share owns a bit less of the company.
Sales by quarter
Sales by quarter
Quarter toAmount
December 2024$5m
March 2025$10m
June 2025$0
September 2025$0
December 2025$0
March 2026Not reported
June 2026$1m
September 2026$10m
Profit by quarter
Profit by quarter
Quarter toAmount
December 2024-$53m
March 2025-$34m
June 2025-$52m
September 2025-$51m
December 2025-$240m
March 2026-$81m
June 2026-$111m
September 2026-$109m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
16 March 2026
Next quarterly (estimated, 10-Q)
4 February 2027

Who owns it

None of the long-term investors we follow own it. 145 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

9 investors own more than 5%.

  • FMR LLC
    Passive investor
    at least 14.3%+3.3 pts
    (filed with 1 related holder)
    Since 31 December 2025
  • at least 12.4%+2.3 pts
    (filed with 3 related holders)
    Since 30 September 2026
  • Ocean Prominent Limited
    Passive investor
    at least 10.4%+1.0 pts
    (filed with 1 related holder)
    Since 26 August 2026
  • Simeon George
    Passive investor
    at least 9.4%
    (filed with 5 related holders)
    Since 9 October 2025
    What they said

    The Funds acquired their respective shares for investment purposes. Depending on market conditions, their continuing evaluation of the business and prospects of the Issuer and other factors, the Funds and other Reporting Persons may dispose of or acquire additional shares of the…

    Read the filing
  • SR One Capital Management, LLC
    Passive investor
    at least 7.7%−1.7 pts
    (filed with 7 related holders)
    Since 13 August 2026
    What they said

    Not applicable.

    Read the filing
  • MOULDER LEON O JR
    Insider or founder
    at least 5.1%+0.3 pts
    (filed with 2 related holders)
    Since 29 April 2026
    What they said

    The information set forth in Item 3 of this Statement is incorporated herein by reference. Mr. Moulder serves as the Chairman of the Issuer's Board of Directors and as its Chief Executive Officer. In such capacity, Mr. Moulder has influence over the corporate activities of the…

    Read the filing
  • BlackRock, Inc.
    Passive investor
    5.0%
    Since 30 September 2026
  • Enavate Sciences GP, LLC
    Passive investor
    at least 4.9%−2.4 pts
    (filed with 1 related holder)
    Since 19 August 2026
  • Patrick G. Enright
    Passive investor
    at least 4.9%
    (filed with 5 related holders)
    Since 9 October 2025
    What they said

    The information set forth in Item 4 of the Original Schedule 13D is incorporated herein by reference.

    Read the filing
  • Novo Holdings A/S
    Passive investor
    Sold down below 5%
    Since 30 September 2025
  • Xencor, Inc.
    Passive investor
    Sold down below 5%
    Since 30 September 2026

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 4 insiders bought $11m of shares on the open market.

  • MOULDER LEON O JR
    Chief Executive Officer, Director
    Bought
    Date
    18 May 2026
    Shares
    60,000
    Price
    $16.88
    Value
    $1m
  • MOULDER LEON O JR
    Chief Executive Officer, Director
    Bought
    Date
    29 April 2026
    Shares
    35,000
    Price
    $17.62
    Value
    $616,700
  • MOULDER LEON O JR
    Chief Executive Officer, Director
    Bought
    Date
    28 April 2026
    Shares
    25,000
    Price
    $18.02
    Value
    $450,500
  • Lu Hongbo
    Director
    Bought
    Date
    31 March 2026
    Shares
    3,768
    Price
    $18.63
    Value
    $70,198
  • Kiselak Tomas
    Director
    Bought
    Date
    31 March 2026
    Shares
    150,000
    Price
    $20.00
    Value
    $3m
  • MOULDER LEON O JR
    Chief Executive Officer, Director
    Bought
    Date
    31 March 2026
    Shares
    34,000
    Price
    $19.31
    Value
    $656,540
  • Lu Hongbo
    Director
    Bought
    Date
    31 March 2026
    Shares
    75,000
    Price
    $20.00
    Value
    $2m
  • MOULDER LEON O JR
    Chief Executive Officer, Director
    Bought
    Date
    30 March 2026
    Shares
    20,000
    Price
    $18.23
    Value
    $364,600
  • Allen Patricia L
    Director
    Bought
    Date
    13 February 2026
    Shares
    4,160
    Price
    $26.36
    Value
    $109,658
  • Allen Patricia L
    Director
    Bought
    Date
    12 February 2026
    Shares
    15,700
    Price
    $24.85
    Value
    $390,088

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 16 Mar 2026, plus the 10-Q filed 5 Nov 2026 and 6 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.